19. Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry . 20.Known or suspected h ypersensitivity to an y of the VBIR -2 components. 21.Other acute or chronic medical or p sychiatric condition, including recent (within the past y ear) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with t he interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study . 22.COVID -19/SARS -CoV2: SARS -CoV2 testing is not mandated for entry into this protocol. However, testing should fo llow local clinical practice standards and requirements. A positive result on an approved test, even if the participant is asymptomatic, excludes a participant from this trial. 23.Investigator site staff members directl y involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Pfizer emplo yees, including their famil y members, directly involved in the conduct of the study . 24.Fertile male participants and female participant s of childbearing potential who are unwilling or unable to use 2 highl y effective methods of contraception as outlined in this protocol for the duration of the study and for at least 5 months after the last dose of investigational product [per Section 4.3below] . PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 714.2.2. Part 2 Exclusion Criteria Participants with any of the following characteristics/conditions will not be included in the study : 1.Participants with known sy mptomatic brain metastases, with the following 2 exceptions: a.Previously Diagnosed Brain Metastases: Participants with previously diagnosed brain metastases are eligible if (a) they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry , (b) have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable for 3 months (confirmed by MRI). b.Screening -Detected Brain Metastases: Participants with newly diagnosed brain metastases identified b y a screening brain MRI who are clinically asymptomatic are eligible if (a) the Investigator deems their clinical status acceptable for participation in the trial and (b) all other i nclusion and exclusion criteria are satisfied, including being neurologicall y stable for 3 months since the screening brain MRI . A baseline MRI at screening is to be conducted onl y if clinically indicated, based on the treating Investigator’s judgement . 2. H istory of prior malignancy other than the disease under study within the past 3 years excluding successfully resected treated basal cell carcinoma or squamous cell carcinoma of the skin or adequatel y treated carcinoma in situ. 3.Participants with high -volume or visceral spread of disease, or those who are symptomatic from their disease, such that they are at risk for life threatening complications in the short term. Examples include participants with uncontrolled pleural, pericardial, or peritoneal effusions; pulmonary lymphangitis; and over 50% liver involvement. Note: Participants with indwelling catheter(s) for drainage, or requirement for intermittent drainage no more frequently than monthl y, will be considered eligible. 4.Participants with intolerance to o r who have had (Grade 3) allergic or anaphy lactic reaction to antibodies or infused therapeutic proteins. 5.Major surgery within 4 weeks prior to first dose. 6.External beam radiation therap y to large areas of the thorax or other sites within 4 weeks prior to first dose; focal, palliative radiation within 2 weeks of first dose. 7.Systemic anticancer therapy within 2 weeks prior to first dose. 8. Participant has AE(s) due to cancer therapeutics administered >4 weeks earlier, which have not recovered to CTCAE Grade 1(except alopecia, and except for AEs not constituting a safety risk by investigator judgment). PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 729.Active and clinicall y significant bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficien cy virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness. HIV seropositive participants, who are health y and low -risk for AIDS -related outcomes,143may qualify for inclusion in the study after discussion with the Sponsor. The following criteria for immune status and HIV ongoing therap y must be met for a HIV seropositive participant to be eligible for the study : a.Immune status criter ia: CD4+T-cell counts ≥350 cells/ μL at the stud y start; No history of AIDS- defining opportunistic infections; Only remote AIDS -defining opportunistic infections in the past and none in 1 y ear prior to study start. b.Ongoing HIV therap y criteria: Must be receiving recommended concurrent ART treatment according to NIH guidelines;144 Began ART treatment >4 weeks prior to stud y start (to ensure ART is tolerated and toxicities are not confused with study drug toxicities); HIV viral load < 400 copies/mL for >4 weeks prior to study start (to ensure ART is tolerated and HIV controlled). Anti- retroviral medications should be listed as concomitant medication. Equivocal cases of viral hepatitis may be eligible if they have a negative viral load. 10. Receipt of an immunosuppressive dose of corticosteroids (ie, 10 mg prednisone daily or equivalent) or other immunosuppressive medication (eg, methotrexate, rapam ycin) within 2 weeks of registration. Note: Participants with adrenal insufficiency may take 5mg of prednisone or equivalent daily. Topical applications, inhaled spray s, eye drops or local injections of corticosteroids are allowed. Low dose corticosteroids for a short duration [5 mg once daily (QD) prednisone for 2 weeks] as sy mptomatic treatment and upon with discussion with the sponsor is allowed. 11.History of or active autoimmune disorders (including but not limited to: my asthenia gravis, thy roiditis, pneu monitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma) and other conditions that alter the immune sy stem. Active inflammatory gastrointestinal disease, Crohn’s disease, ulcerative colitis, and PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 73primary sclerosing chol angitis are excluded; however, non -immune mediated gastroesophageal reflux disease (esophagitis/gastritis) under treatment with proton pump inhibitors is allowed (assuming no drug interaction potential). 12.Acet ylcholine receptor binding antibod y ≥0.5 nmol/L . 13.Abnormal neurologic examination at screening indicating possible underly ing autoimmune disorder(s). 14.Any of the following in the previous 12 months or currentl y: myocardial infarction, severe/unstable angina, coronary /peripheral artery by pass graft, s ymptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism, as well as ongoing cardiac d ysrhythmias of NCI CTCAE Grade 2, atrial fibrillation of any grade, or QTc interval >470 msec at screening. 15.Cardiac Troponin -I (cTnI) must be measured and found to be within the normal reference range before the administration of the first dose. Abnormal circulating levels of cTnI are exclusionary . 16. Individuals in whom a skin- fold measurement of the cutaneous a nd subcutaneous tissue for 2 or more eligible injection sites exceeds 50 millimeters (mm). 17. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate IM injection. 18.Current use of an y implanted electronic stimulation d evice, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators. 19.Presence of an y surgical or traumatic metal implants at the site of administration (medial deltoid muscles or overl ying ski n or vastus lateralis muscle). 20.Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therap y). 25.Severel y symptomatic Chronic Obstructive Pulmonary Disease (eg, requiring ambulatory oxygen).